2021
DOI: 10.1007/s12275-021-0562-5
|View full text |Cite
|
Sign up to set email alerts
|

GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABAB receptor signaling

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(20 citation statements)
references
References 40 publications
1
16
0
Order By: Relevance
“…Numerous studies have shown that adjuvant 5-FU-based chemotherapy can improve the 5-year overall survival (OS) of stage II and III patients compared to surgery alone ( 41 , 42 ). However, the prognosis of such patients still remains poor, mainly due to 5-FU resistance ( 43 , 44 ). Herein, we have made several novel observations.…”
Section: Discussionmentioning
confidence: 99%
“…Numerous studies have shown that adjuvant 5-FU-based chemotherapy can improve the 5-year overall survival (OS) of stage II and III patients compared to surgery alone ( 41 , 42 ). However, the prognosis of such patients still remains poor, mainly due to 5-FU resistance ( 43 , 44 ). Herein, we have made several novel observations.…”
Section: Discussionmentioning
confidence: 99%
“…Several Lactobacillus species produce a wide range of neurotransmitters (Yong et al, 2019) (Table 2). GABA can be synthesized by certain Bifidobacterium species (Barrett et al, 2012), Bacteroides fragilis (Strandwitz et al, 2019), and L. plantarum (An et al, 2021). Furthermore, microbial species, including L. plantarum, B. subtilis, and S. aureus, can produce Ach (Horiuchi et al, 2003;Koussoulas et al, 2018;O'Donnell et al, 2020).…”
Section: Neurotransmittersmentioning
confidence: 99%
“…Moreover, Lactobacillus was more abundant in CRC patients with PIK3CA mutations in our study. Lactobacillus inhibits the growth of colorectal cancer by secreting short-chain fatty acids (SCFAs) that enhance the intestinal barrier function [ 32 ]. Taken together, our findings are supported by the above-mentioned reports, which highlight the clinical relevance of Faecalibacterium and Lactobacillus in the development of CRC and suggest their potential to become a therapeutic agent by producing bioactive compounds that may benefit the host.…”
Section: Discussionmentioning
confidence: 99%